Anemia as a Risk Factor for Kidney Function Decline in Individuals With Heart Failure

      Chronic kidney disease (CKD), anemia, and declining kidney function are recognized as risk factors for adverse outcomes in patients with heart failure. This analysis was conducted to evaluate whether anemia is a risk factor for kidney function decrease in patients with heart failure. Data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized trial of enalapril versus placebo in patients with ejection fractions ≤35%, were analyzed. After randomization, creatinine measurements were taken at 2 weeks, 6 weeks, 4 months, and every 4 months thereafter. The glomerular filtration rate (GFR) was estimated using the Modification of Diet in Renal Disease Study (MDRD) equation, and GFR slope was calculated. “Rapid decrease” was defined as a decrease in the GFR of ≥6 ml/min/1.73 m2/year. Anemia was defined as baseline hematocrit <36%. Multivariate logistic regression weighted by the number of GFR assessments was used to test the relation between anemia and rapid decrease. We also evaluated whether CKD (baseline GFR ≤60 ml/min/1.73 m2) modified the relation between anemia and rapid decrease. In the 6,360 subjects, the mean age was 59 years, 31% had CKD, and 6% had anemia. Median follow-up was 2 years. In multivariate analysis, anemia was associated with a 1.30 increased odds (95% confidence interval 1.18 to 1.45) of rapid decrease in GFR. In subjects with CKD, anemia was associated with a 1.71 increased odds (95% confidence interval 1.43 to 2.05) of rapid decrease, while in subjects without CKD, anemia was associated with a 1.16 increased odds (95% confidence interval 1.03 to 1.31) of rapid decrease (p for interaction <0.001). In conclusion, anemia is associated with a rapid decrease in kidney function in patients with heart failure, particularly in those with underlying CKD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Herzog C.A.
        • Muster H.A.
        • Li S.
        • Collins A.J.
        Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population.
        J Card Fail. 2004; 10: 467-472
        • Silverberg D.S.
        • Wexler D.
        • Blum M.
        • Tchebiner J.
        • Sheps D.
        • Keren G.
        • Schwartz D.
        • Baruch R.
        • Yachnin T.
        • Shaked M.
        • et al.
        The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.
        Clin Nephrol. 2002; 58: S37-S45
        • Anand I.S.
        • Kuskowski M.A.
        • Rector T.S.
        • Florea V.G.
        • Glazer R.D.
        • Hester A.
        • Chiang Y.T.
        • Aknay N.
        • Maggioni A.P.
        • Opasich C.
        • et al.
        Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
        Circulation. 2005; 112: 1121-1127
        • Mancini D.M.
        • Katz S.D.
        • Lang C.C.
        • LaManca J.
        • Hudaihed A.
        • Androne A.S.
        Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.
        Circulation. 2003; 107: 294-299
        • Al-Ahmad A.
        • Rand W.M.
        • Manjunath G.
        • Konstam M.A.
        • Salem D.N.
        • Levey A.S.
        • Sarnak M.J.
        Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction.
        J Am Coll Cardiol. 2001; 38: 955-962
        • Levin A.
        • Thompson C.R.
        • Ethier J.
        • Carlisle E.J.
        • Tobe S.
        • Mendelssohn D.
        • Burgess E.
        • Jindal K.
        • Barrett B.
        • Singer J.
        • Djurdjev O.
        Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.
        Am J Kidney Dis. 1999; 34: 125-134
        • Keane W.F.
        • Brenner B.M.
        • de Zeeuw D.
        • Grunfeld J.P.
        • McGill J.
        • Mitch W.E.
        • Ribeiro A.B.
        • Shahinfar S.
        • Simpson R.L.
        • Snapinn S.M.
        • Toto R.
        The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.
        Kidney Int. 2003; 63: 1499-1507
        • Forman D.E.
        • Butler J.
        • Wang Y.
        • Abraham W.T.
        • O’Connor C.M.
        • Gottlieb S.S.
        • Loh E.
        • Massie B.M.
        • Rich M.W.
        • Stevenson L.W.
        • et al.
        Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.
        J Am Coll Cardiol. 2004; 43: 61-67
        • Butler J.
        • Forman D.E.
        • Abraham W.T.
        • Gottlieb S.S.
        • Loh E.
        • Massie B.M.
        • O’Connor C.M.
        • Rich M.W.
        • Stevenson L.W.
        • Wang Y.
        • et al.
        Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.
        Am Heart J. 2004; 147: 331-338
        • Khan N.A.
        • Ma I.
        • Thompson C.R.
        • Humphries K.
        • Salem D.N.
        • Sarnak M.J.
        • Levin A.
        Kidney function and mortality among patients with left ventricular systolic dysfunction.
        J Am Soc Nephrol. 2006; 17: 244-253
        • Vlagopoulos P.T.
        • Tighiouart H.
        • Weiner D.E.
        • Griffith J.
        • Pettitt D.
        • Salem D.N.
        • Levey A.S.
        • Sarnak M.J.
        Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease.
        J Am Soc Nephrol. 2005; 16: 3403-3410
        • Jurkovitz C.T.
        • Abramson J.L.
        • Vaccarino L.V.
        • Weintraub W.S.
        • McClellan W.M.
        Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based Atherosclerosis Risk in Communities (ARIC) study.
        J Am Soc Nephrol. 2003; 14: 2919-2925
      1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293–302.

        • Levey A.S.
        • Bosch J.P.
        • Lewis J.B.
        • Greene T.
        • Rogers N.
        • Roth D.
        • Modification of Diet in Renal Disease Study Group
        A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.
        Annals Int Med. 1999; 130: 461-470
        • Gerson A.
        • Hwang W.
        • Fiorenza J.
        • Barth K.
        • Kaskel F.
        • Weiss L.
        • Zelikovsky N.
        • Fivush B.
        • Furth S.
        Anemia and health-related quality of life in adolescents with chronic kidney disease.
        Am J Kidney Dis. 2004; 44: 1017-1023
        • Hebert L.A.
        • Greene T.
        • Levey A.
        • Falkenhain M.E.
        • Klahr S.
        High urine volume and low urine osmolality are risk factors for faster progression of renal disease.
        Am J Kidney Dis. 2003; 41: 962-971
        • Wright Jr, J.T.
        • Bakris G.
        • Greene T.
        • Agodoa L.Y.
        • Appel L.J.
        • Charleston J.
        • Cheek D.
        • Douglas-Baltimore J.G.
        • Gassman J.
        • Glassock R.
        • et al.
        Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
        JAMA. 2002; 288: 2421-2431
        • Klahr S.
        Role of dietary protein and blood pressure in the progression of renal disease.
        Kidney Int. 1996; 49: 1783-1786
        • Gouva C.
        • Nikolopoulos P.
        • Ioannidis J.P.
        • Siamopoulos K.C.
        Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial.
        Kidney Int. 2004; 66: 753-760
        • Knight E.L.
        • Glynn R.J.
        • McIntyre K.M.
        • Mogun H.
        • Avorn J.
        Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the Studies of Left Ventricular Dysfunction (SOLVD).
        Am Heart J. 1999; 138: 849-855
        • World Health Organization
        Nutritional anaemias: a report of a WHO scientific group.
        World Health Organ Tech Rep Ser. 1968; 405: 3-37
        • Silverberg D.S.
        • Wexler D.
        • Sheps D.
        • Blum M.
        • Keren G.
        • Baruch R.
        • Schwartz D.
        • Yachnin T.
        • Steinbruch S.
        • Shapira I.
        • et al.
        The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.
        J Am Coll Cardiol. 2001; 37: 1775-1780
        • Fine L.G.
        • Bandyopadhay D.
        • Norman J.T.
        Is there a common mechanism for the progression of different types of renal diseases other than proteinuria?.
        Kidney Int Suppl. 2000; 75: S22-S26
        • Orphanides C.
        • Fine L.G.
        • Norman J.T.
        Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism.
        Kidney Int. 1997; 52: 637-647
        • Nangaku M.
        Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure.
        Nephron Exp Nephrol. 2004; 98: e8-e12
        • Rossert J.
        • Fouqueray B.
        • Boffa J.J.
        Anemia management and the delay of chronic renal failure progression.
        J Am Soc Nephrol. 2003; 14: S173-S177
        • Katz A.M.
        The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart.
        Ann Intern Med. 1994; 121: 363-371
        • Winkelmayer W.C.
        • Kewalramani R.
        • Rutstein M.
        • Gabardi S.
        • Vonvisger T.
        • Chandraker A.
        Pharmacoepidemiology of anemia in kidney transplant recipients.
        J Am Soc Nephrol. 2004; 15: 1347-1352
        • Albitar S.
        • Genin R.
        • Fen-Chong M.
        • Serveaux M.O.
        • Bourgeon B.
        High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.
        Nephrol Dial Transplant. 1998; 13: 1206-1210